Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2231-2238

  Matsuda, Yoshiki ^a   Konno, Yoshihiro ^a   Satsukawa, Masahiro ^a   Kobayashi, Taro ^b   Takimoto, Yu ^b   Morisaki, Kunihiko ^b   Yamashita, Shinji ^c  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

^b CHARLES RIVER LABORATORIES   (United States)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; FAMOTIDINE; FELODIPINE; FEXOFENADINE; GLUCOSE; INDOMETACIN; LIDOCAINE; MIDAZOLAM; PHENAZONE; PROTEIN; RALOXIFENE; SULPIRIDE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; INTESTINE ABSORPTION; LIVER; LIVER BLOOD FLOW; MALE; METABOLISM; NONHUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RAT; SIMULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPYRINE; BIOLOGICAL AVAILABILITY; CATHETERIZATION; INTESTINAL ABSORPTION; INTESTINES; LIVER; MALE; MICROSOMES, LIVER; PHARMACOKINETICS; PORTAL VEIN; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW;

ANIMALIA; RATTUS;

EID: 84869105598     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048223     Document Type: Article

References (27)

1. Chindavijak B, Belpaire FM, De Smet F, and Bogaert MG (1988) Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat. J Pharmacol Exp Ther 246:1075-1079.
2. De Rick AF, Belpaire FM, Dello C, and Bogaert MG (1987) Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog. J Pharmacol Exp Ther 241:289-293.
3. Furukawa T, Nakamori F, Tetsuka K, Naritomi Y, Moriguchi H, Yamano K, Terashita S, and Teramura T (2012) Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Drug Metab Pharmacokinet 27:171-180.
4. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
5. Hucker HB, Zacchei AG, Cox SV, Brodie DA, and Cantwell NH (1966) Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 153:237-249.
6. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
7. Kamath AV, Yao M, Zhang Y, and Chong S (2005) Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233-239.
8. Kanazu T, Okamura N, Yamaguchi Y, Baba T, and Koike M (2005) Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 35:305-317.
9. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
10. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
11. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, et al. (2011) Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39:1495-1502.
12. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, and Greenblatt DJ (2002) In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237.
13. Kuze J, Mutoh T, Takenaka T, Morisaki K, Nakura H, Hanioka N, and Narimatsu S (2009) Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 39:871-880.
14. Lee K and Thakker DR (1999) Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 88:680-687.
15. Mizuma T (2002) Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab Pharmacokinet 17:496-506.
16. Murakami T, Nakanishi M, Yoshimori T, Okamura N, Norikura R, and Mizojiri K (2003) Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252-260.
17. Nishimuta H, Sato K, Yabuki M, and Komuro S (2011) Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26:592-601.
18. Rane A, Wilkinson GR, and Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424.
19. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304-1310.
20. Strelevitz TJ, Foti RS, and Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
21. Takahashi M, Washio T, Suzuki N, Igeta K, and Yamashita S (2009) The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343-4353.
22. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
23. Tolle-Sander S, Rautio J, Wring S, Polli JW, and Polli JE (2003) Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20:757-764.
24. von Moltke LL, Greenblatt DJ, Harmatz JS, and Shader RI (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47:268-276.
25. Watanabe K, Sawano T, Terada K, Endo T, Sakata M, and Sato J (2002) Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull 25:885-890.
26. Wilkinson GR and Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
27. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, and Hori R (1985) Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther 235:513-520.